All-Bio Science Inc. Announces Board Approval of Q1 2026 Consolidated Financial Statements
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
All-Bio Science Inc. announced that its Board of Directors approved the consolidated financial statements for the first quarter of 2026 (January 1 to March 31). The company reported revenues of NT$2,823k, an operating loss of NT$83,470k, and a pre-tax net loss of NT$75,995k, resulting in a basic loss per share of NT$0.5.